Idendifying biomarkers of lung cancer in the post-genomic era

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the last two decades, we have witnessed an exponential growth of our knowledge on cell growth and neoplastic transformation at the molecular level. There is high expectation that these advances will be translated into further improvement in the care of cancer patients, especially in the areas of diagnosis, prognosis and treatment. With the completion of the human genome project and numerous studies on gene expression analyses in lung cancer, our challenge is to understand the tumor morphological changes at the molecular level, which will ultimately lead to novel approaches for patient care. This review will summarize methods for identifying biomarkers of lung cancer and molecular/genetic changes that have been investigated as candidate diagnostic, prognostic and predictive markers for lung cancer. A more concerted and global approach to study the clinical relevance of molecular changes in lung cancers is required in the future.

Original languageEnglish (US)
Pages (from-to)319-331
Number of pages13
JournalCurrent Pharmacogenomics
Volume3
Issue number4
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Lung Neoplasms
Biomarkers
Patient Care
Neoplastic Cell Transformation
Human Genome Project
Growth
Molecular Biology
Neoplasms
Gene Expression
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Genetics

Cite this

Idendifying biomarkers of lung cancer in the post-genomic era. / Xie, Jingwu.

In: Current Pharmacogenomics, Vol. 3, No. 4, 12.2005, p. 319-331.

Research output: Contribution to journalArticle

@article{1e82df491e454c5097f535c7392df177,
title = "Idendifying biomarkers of lung cancer in the post-genomic era",
abstract = "In the last two decades, we have witnessed an exponential growth of our knowledge on cell growth and neoplastic transformation at the molecular level. There is high expectation that these advances will be translated into further improvement in the care of cancer patients, especially in the areas of diagnosis, prognosis and treatment. With the completion of the human genome project and numerous studies on gene expression analyses in lung cancer, our challenge is to understand the tumor morphological changes at the molecular level, which will ultimately lead to novel approaches for patient care. This review will summarize methods for identifying biomarkers of lung cancer and molecular/genetic changes that have been investigated as candidate diagnostic, prognostic and predictive markers for lung cancer. A more concerted and global approach to study the clinical relevance of molecular changes in lung cancers is required in the future.",
author = "Jingwu Xie",
year = "2005",
month = "12",
doi = "10.2174/157016005774913185",
language = "English (US)",
volume = "3",
pages = "319--331",
journal = "Current Pharmacogenomics",
issn = "1570-1603",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Idendifying biomarkers of lung cancer in the post-genomic era

AU - Xie, Jingwu

PY - 2005/12

Y1 - 2005/12

N2 - In the last two decades, we have witnessed an exponential growth of our knowledge on cell growth and neoplastic transformation at the molecular level. There is high expectation that these advances will be translated into further improvement in the care of cancer patients, especially in the areas of diagnosis, prognosis and treatment. With the completion of the human genome project and numerous studies on gene expression analyses in lung cancer, our challenge is to understand the tumor morphological changes at the molecular level, which will ultimately lead to novel approaches for patient care. This review will summarize methods for identifying biomarkers of lung cancer and molecular/genetic changes that have been investigated as candidate diagnostic, prognostic and predictive markers for lung cancer. A more concerted and global approach to study the clinical relevance of molecular changes in lung cancers is required in the future.

AB - In the last two decades, we have witnessed an exponential growth of our knowledge on cell growth and neoplastic transformation at the molecular level. There is high expectation that these advances will be translated into further improvement in the care of cancer patients, especially in the areas of diagnosis, prognosis and treatment. With the completion of the human genome project and numerous studies on gene expression analyses in lung cancer, our challenge is to understand the tumor morphological changes at the molecular level, which will ultimately lead to novel approaches for patient care. This review will summarize methods for identifying biomarkers of lung cancer and molecular/genetic changes that have been investigated as candidate diagnostic, prognostic and predictive markers for lung cancer. A more concerted and global approach to study the clinical relevance of molecular changes in lung cancers is required in the future.

UR - http://www.scopus.com/inward/record.url?scp=28444452314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444452314&partnerID=8YFLogxK

U2 - 10.2174/157016005774913185

DO - 10.2174/157016005774913185

M3 - Article

AN - SCOPUS:28444452314

VL - 3

SP - 319

EP - 331

JO - Current Pharmacogenomics

JF - Current Pharmacogenomics

SN - 1570-1603

IS - 4

ER -